Immune Responses Induced by mRNA Vaccination in Mice, Monkeys and Humans

Abstract

In this concise review, we summarize the concepts behind mRNA vaccination. We discuss the innate and adaptive immune response generated by mRNA vaccines in different animal models and in humans. We give examples of viral infections where mRNA vaccines have shown to induce potent responses and we discuss in more detail the recent SARS-CoV-2 mRNA vaccine trials in humans.

References 84

1. 1.

   Wolff J., Malone R., Williams P., Chong W., Acsadi G., Jani A., Felgner P. Direct gene transfer into mouse muscle in vivo. Science. 1990;247:1465-1468.

   Not in our library10.1126/science.1690918

2. 2.

   Ulmer J.B., Donnelly J.J., Parker S.E., Rhodes G.H., Felgner P.L., Dwarki V.J., Gromkowski S.H., Deck R.R., DeWitt C.M., Friedman A., et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science. 1993;259:1745-1749.

   Not in our library10.1126/science.8456302

3. 3.

   Zhou X., Berglund P., Rhodes G., Parker S.E., Jondal M., Liljestrom P. Self-replicating Semliki Forest virus RNA as recombinant vaccine. Vaccine. 1994;12:1510-1514.

   Not in our library10.1016/0264-410x(94)90074-4

4. 4.

   Martinon F., Krishnan S., Lenzen G., Magne R., Gomard E., Guillet J.G., Levy J.P., Meulien P. Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA. Eur. J. Immunol. 1993;23:1719-1722.

   Not in our library10.1002/eji.1830230749

5. 5.

   Kariko K., Muramatsu H., Welsh F.A., Ludwig J., Kato H., Akira S., Weissman D. Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol. Ther. 2008;16:1833-1840.

   Not in our library10.1038/mt.2008.200

6. 6.

   Schlake T., Thess A., Fotin-Mleczek M., Kallen K.J. Developing mRNA-vaccine technologies. RNA Biol. 2012;9:1319-1330.

   Not in our library10.4161/rna.22269

7. 7.

   Graham B.S., Mascola J.R., Fauci A.S. Novel Vaccine Technologies: Essential Components of an Adequate Response to Emerging Viral Diseases. JAMA. 2018;319:1431-1432.

   Not in our library10.1001/jama.2018.0345

8. 8.

   Liang F., Lindgren G., Lin A., Thompson E.A., Ols S., Rohss J., John S., Hassett K., Yuzhakov O., Bahl K., et al. Efficient Targeting and Activation of Antigen-Presenting Cells In Vivo after Modified mRNA Vaccine Administration in Rhesus Macaques. Mol. Ther. 2017;25:2635-2647.

   Not in our library10.1016/j.ymthe.2017.08.006

9. 9.

   Hassett K.J., Benenato K.E., Jacquinet E., Lee A., Woods A., Yuzhakov O., Himansu S., Deterling J., Geilich B.M., Ketova T., et al. Optimization of Lipid Nanoparticles for Intramuscular Administration of mRNA Vaccines. Mol. Ther. Nucleic. Acids. 2019;15:1-11.

   Not in our library10.1016/j.omtn.2019.01.013

10. 10.

    Kulkarni J.A., Cullis P.R., van der Meel R. Lipid Nanoparticles Enabling Gene Therapies: From Concepts to Clinical Utility. Nucleic. Acid. Ther. 2018;28:146-157.

    Not in our library10.1089/nat.2018.0721

11. 11.

    Sands H., Gorey-Feret L.J., Cocuzza A.J., Hobbs F.W., Chidester D., Trainor G.L. Biodistribution and metabolism of internally 3H-labeled oligonucleotides. I. Comparison of a phosphodiester and a phosphorothioate. Mol. Pharmacol. 1994;45:932-943.

    Not in our library

12. 12.

    Reichmuth A.M., Oberli M.A., Jaklenec A., Langer R., Blankschtein D. mRNA vaccine delivery using lipid nanoparticles. Ther. Deliv. 2016;7:319-334.

    Not in our library10.4155/tde-2016-0006

13. 13.

    Chen S., Tam Y.Y.C., Lin P.J.C., Sung M.M.H., Tam Y.K., Cullis P.R. Influence of particle size on the in vivo potency of lipid nanoparticle formulations of siRNA. J. Control. Release. 2016;235:236-244.

    Not in our library10.1016/j.jconrel.2016.05.059

14. 14.

    Eygeris Y., Patel S., Jozic A., Sahay G. Deconvoluting Lipid Nanoparticle Structure for Messenger RNA Delivery. Nano Lett. 2020;20:4543-4549.

    Not in our library10.1021/acs.nanolett.0c01386

15. 15.

    Lee S., Cheng Q., Yu X., Liu S., Johnson L., Siegwart D.J. A Systematic Study of Unsaturation in Lipid Nanoparticles Leads to Improved mRNA Transfection In Vivo. Angew Chem. Int. Ed. Engl. 2020.

    Not in our library10.1002/anie.202013927

16. 16.

    Persano S., Guevara M.L., Li Z., Mai J., Ferrari M., Pompa P.P., Shen H. Lipopolyplex potentiates anti-tumor immunity of mRNA-based vaccination. Biomaterials. 2017;125:81-89.

    Not in our library10.1016/j.biomaterials.2017.02.019

17. 17.

    Amanna I.J., Carlson N.E., Slifka M.K. Duration of humoral immunity to common viral and vaccine antigens. N. Engl. J. Med. 2007;357:1903-1915.

    Not in our library10.1056/nejmoa066092

18. 18.

    Monath T.P., Gershman M., Erin Staples J., Barrett A.D.T., Plotkin S.A., Orenstein W.A., Offit P.A. Yellow fever vaccine. Vaccines. 2013;870-968.

    Not in our library10.1016/b978-1-4557-0090-5.00043-4

19. 19.

    Medical Advisory Committee of the Immune Deficiency Foundation, Shearer W.T., Fleisher T.A., Buckley R.H., Ballas Z., Ballow M., Blaese R.M., Bonilla F.A., Conley M.E., Cunningham-Rundles C., et al. Recommendations for live viral and bacterial vaccines in immunodeficient patients and their close contacts. J. Allergy. Clin. Immunol. 2014;133:961-966.

    Not in our library10.1016/j.jaci.2013.11.043

20. 20.

    Francica J.R., Sheng Z., Zhang Z., Nishimura Y., Shingai M., Ramesh A., Keele B.F., Schmidt S.D., Flynn B.J., Darko S., et al. Analysis of immunoglobulin transcripts and hypermutation following SHIV(AD8) infection and protein-plus-adjuvant immunization. Nat. Commun. 2015;6:6565.

    Not in our library10.1038/ncomms7565

21. 21.
    Induction of Robust B Cell Responses after Influenza mRNA Vaccination Is Accompanied by Circulating Hemagglutinin-Specific ICOS+ PD-1+ CXCR3+ T Follicular Helper Cells · 2017

    Corrected
22. 22.
    RNA-Based Vaccines in Cancer Immunotherapy · 2015

    No notice
23. 23.

    Akinc A., Querbes W., De S., Qin J., Frank-Kamenetsky M., Jayaprakash K.N., Jayaraman M., Rajeev K.G., Cantley W.L., Dorkin J.R., et al. Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol. Ther. 2010;18:1357-1364.

    Not in our library10.1038/mt.2010.85

24. 24.

    van den Elzen P., Garg S., Leon L., Brigl M., Leadbetter E.A., Gumperz J.E., Dascher C.C., Cheng T.Y., Sacks F.M., Illarionov P.A., et al. Apolipoprotein-mediated pathways of lipid antigen presentation. Nature. 2005;437:906-910.

    Not in our library10.1038/nature04001

25. 25.

    Kranz L.M., Diken M., Haas H., Kreiter S., Loquai C., Reuter K.C., Meng M., Fritz D., Vascotto F., Hefesha H., et al. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature. 2016;534:396-401.

    Not in our library10.1038/nature18300

26. 26.

    Lazzaro S., Giovani C., Mangiavacchi S., Magini D., Maione D., Baudner B., Geall A.J., De Gregorio E., D’Oro U., Buonsanti C. CD8 T-cell priming upon mRNA vaccination is restricted to bone-marrow-derived antigen-presenting cells and may involve antigen transfer from myocytes. Immunology. 2015;146:312-326.

    Not in our library10.1111/imm.12505

27. 27.
    Linkage between endosomal escape of LNP-mRNA and loading into EVs for transport to other cells · 2019

    No notice
28. 28.

    Brito L.A., Chan M., Shaw C.A., Hekele A., Carsillo T., Schaefer M., Archer J., Seubert A., Otten G.R., Beard C.W., et al. A cationic nanoemulsion for the delivery of next-generation RNA vaccines. Mol. Ther. 2014;22:2118-2129.

    Not in our library10.1038/mt.2014.133

29. 29.

    Pardi N., Tuyishime S., Muramatsu H., Kariko K., Mui B.L., Tam Y.K., Madden T.D., Hope M.J., Weissman D. Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes. J. Control. Release. 2015;217:345-351.

    Not in our library10.1016/j.jconrel.2015.08.007

30. 30.

    Bahl K., Senn J.J., Yuzhakov O., Bulychev A., Brito L.A., Hassett K.J., Laska M.E., Smith M., Almarsson O., Thompson J., et al. Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses. Mol. Ther. 2017;25:1316-1327.

    Not in our library10.1016/j.ymthe.2017.03.035

31. 31.

    Kowalczyk A., Doener F., Zanzinger K., Noth J., Baumhof P., Fotin-Mleczek M., Heidenreich R. Self-adjuvanted mRNA vaccines induce local innate immune responses that lead to a potent and boostable adaptive immunity. Vaccine. 2016;34:3882-3893.

    Not in our library10.1016/j.vaccine.2016.05.046

32. 32.

    Oberli M.A., Reichmuth A.M., Dorkin J.R., Mitchell M.J., Fenton O.S., Jaklenec A., Anderson D.G., Langer R., Blankschtein D. Lipid Nanoparticle Assisted mRNA Delivery for Potent Cancer Immunotherapy. Nano Lett. 2017;17:1326-1335.

    Not in our library10.1021/acs.nanolett.6b03329

33. 33.
    Self-Amplifying RNA Vaccines Give Equivalent Protection against Influenza to mRNA Vaccines but at Much Lower Doses · 2018

    No notice
34. 34.

    Geall A.J., Verma A., Otten G.R., Shaw C.A., Hekele A., Banerjee K., Cu Y., Beard C.W., Brito L.A., Krucker T., et al. Nonviral delivery of self-amplifying RNA vaccines. Proc. Natl. Acad. Sci. USA. 2012;109:14604-14609.

    Not in our library10.1073/pnas.1209367109

35. 35.

    Lindsay K.E., Bhosle S.M., Zurla C., Beyersdorf J., Rogers K.A., Vanover D., Xiao P., Arainga M., Shirreff L.M., Pitard B., et al. Visualization of early events in mRNA vaccine delivery in non-human primates via PET-CT and near-infrared imaging. Nat. Biomed. Eng. 2019;3:371-380.

    Not in our library10.1038/s41551-019-0378-3

36. 36.

    Ols S., Lore K. Imaging the early fate of mRNA vaccines. Nat. Biomed. Eng. 2019;3:331-332.

    Not in our library10.1038/s41551-019-0399-y

37. 37.

    Asselin-Paturel C., Brizard G., Chemin K., Boonstra A., O’Garra A., Vicari A., Trinchieri G. Type I interferon dependence of plasmacytoid dendritic cell activation and migration. J. Exp. Med. 2005;201:1157-1167.

    Not in our library10.1084/jem.20041930

38. 38.

    Simmons D.P., Wearsch P.A., Canaday D.H., Meyerson H.J., Liu Y.C., Wang Y., Boom W.H., Harding C.V. Type I IFN drives a distinctive dendritic cell maturation phenotype that allows continued class II MHC synthesis and antigen processing. J. Immunol. 2012;188:3116-3126.

    Not in our library10.4049/jimmunol.1101313

39. 39.
    Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines · 2017

    No notice
40. 40.

    Liang F., Lindgren G., Sandgren K.J., Thompson E.A., Francica J.R., Seubert A., De Gregorio E., Barnett S., O’Hagan D.T., Sullivan N.J., et al. Vaccine priming is restricted to draining lymph nodes and controlled by adjuvant-mediated antigen uptake. Sci. Transl. Med. 2017;9.

    Not in our library10.1126/scitranslmed.aal2094

Cited by papers we hold 4

• Advances in COVID-19 mRNA vaccine development · 2022
  No notice
• SARS-CoV-2 mRNA Vaccines: Immunological Mechanism and Beyond · 2021
  No notice
• A Comprehensive Review of COVID-19 Virology, Vaccines, Variants, and Therapeutics · 2021
  No notice
• Distinguishing features of current COVID-19 vaccines: knowns and unknowns of antigen presentation and modes of action · 2021
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.